CDXS
Codexis, Inc. (NASDAQ)
Healthcare — Biotechnology
Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Price History
Fundamentals
| Market Cap | $217.24M |
| P/E Ratio (TTM) | - |
| Forward P/E | -6.46 |
| EPS (TTM) | $-0.35 |
| Dividend Yield | - |
| Profit Margin | -40.97% |
| Revenue Growth | 102.10% |
| ROE | -68.90% |
| Debt/Equity | 168.62 |
| Recommendation | None |
| Analyst Target | $6.58 |
| Analysts | 6 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 52.0 |
| Beta | 2.48 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $3.87 |
| 52-Week Low | $0.96 |
| 50-Day Avg | $2.55 |
| 200-Day Avg | $2.02 |
| Avg Volume | 957.2K |
| Volume | 435.4K |
Performance Analysis
NEUTRALCDXS presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:02 UTC
Back to Screener Export Report